Mike Craky

Mike Craky asked about the potential revenue contribution from the prostate market in 2026, particularly ahead of further clinical progression. He also inquired if any BLA-related expenses should be built into G&A for 2026, following the expenses outlined for Q4 2025.

Answer

CEO Michael Dale stated that prostate will not be a significant revenue contributor in 2026, as the company is maintaining discipline and awaiting clinical signals from the initial 10 clinical sites and 100 procedures. He indicated that any potential development spend is already captured in the current guidance. CFO Lindsey Hartley clarified that the $1.9 million G&A impact in Q4 2025 was a one-time stock-based compensation expense directly tied to the BLA approval, implying no new BLA-specific G&A expenses for 2026 beyond what's already factored into guidance.